Physician profile
Daniel Chin
NPI 1497072979
$4,817.56
in general payments reported to CMS, 2019-2025
21 companies · $18.40 in 2025
The $18.40 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,423 · 2020: $864 · 2021: $326 · 2022: $577 · 2023: $411 · 2024: $199 · 2025: $18.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $752.78 | 2019-2022 | |
| Abbvie INC. | $718.38 | 2019-2025 | Vraylar |
| Allergan, INC. | $650.24 | 2019-2020 | |
| Pfizer INC. | $542.06 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $410.67 | 2019-2024 | Farxiga, Breztri |
| Viiv Healthcare Company | $325.43 | 2019-2022 | |
| Novo Nordisk INC | $217.79 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $211.28 | 2019 | |
| Abbott Laboratories | $209.14 | 2019-2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.13 | 2019-2022 | |
| Amarin Pharma, INC. | $144.29 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $108.05 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $94.70 | 2019 | |
| Merck Sharp & Dohme LLC | $78.82 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $50.63 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $38.30 | 2019-2020 | |
| Gilead Sciences, INC. | $36.68 | 2019-2023 | |
| Eisai INC. | $24.87 | 2020 | |
| Amgen INC. | $23.55 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.34 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Chin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.